Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2024-02-09 Regulatory Filings
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-02-09 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to a sales agreement for common stock. It details an offering of shares, terms of sale, compensation to agents, risk factors, and other information typical of a securities offering document. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital raising but is not an earnings release or capital/financing update per se. Given the nature of the document as a prospectus for a stock offering, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high due to clear identification of the document as a prospectus under Rule 424(b)(5) and detailed offering terms.
2024-02-08 English
10-Q
Interim / Quarterly Report Q3 2024
2024-02-08 English
8-K
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate presentations. The text specifically states that the company is furnishing a corporate presentation as Exhibit 99.1, which was presented at a conference and is being posted on the company's website. The document is short (3790 characters) and primarily serves to announce the availability of the presentation rather than containing the full presentation or detailed financial data. According to the 'Menu vs Meal' rule, such a document is an announcement of a report rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2024-02-07 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a letter from Organovo Holdings, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references the Securities Act of 1933 and the filing date of January 26, 2024. The content is a formal request related to a registration statement effectiveness, which is a capital markets activity concerning securities registration and offering. The document is short (1451 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an update related to capital raising filings. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-02-06 English
AMENDMENT NO. 4
Major Shareholding Notification
2024-02-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.